Rezvilutamide: A new "survival extension" tool for metastatic castration-resistant prostate cancer
Prostate cancer is one of the most common malignant tumors of the male reproductive system. Among them, metastatic hormone-sensitive prostate cancer (mHSPC) is characterized by rapid disease progression and high treatment complexity, making it a long-standing focus and challenge in clinical practice. As a novel androgen receptor inhibitor independently developed in China, Reviluamide Tablets (...
0 Comments 0 Shares